Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar;45(3):e16123.
doi: 10.1111/liv.16123. Epub 2024 Oct 7.

Global Epidemiological Impact of PNPLA3 I148M on Liver Disease

Affiliations
Review

Global Epidemiological Impact of PNPLA3 I148M on Liver Disease

Julia Kozlitina et al. Liver Int. 2025 Mar.

Abstract

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) has increased exponentially over the past three decades, in parallel with the global rise in obesity and type 2 diabetes. It is currently the most common cause of liver-related morbidity and mortality. Although obesity has been identified as a key factor in the increased prevalence of MASLD, individual differences in susceptibility are significantly influenced by genetic factors. PNPLA3 I148M (rs738409 C>G) is the variant with the greatest impact on the risk of developing progressive MASLD and likely other forms of steatotic liver disease. This variant is prevalent across the globe, with the risk allele (G) frequency exhibiting considerable variation. Here, we review the contribution of PNPLA3 I148M to global burden and regional differences in MASLD prevalence, focusing on recent evidence emerging from population-based sequencing studies and prevalence assessments. We calculated the population attributable fraction (PAF) as a means of quantifying the impact of the variant on MASLD. Furthermore, we employ quantitative trait locus (QTL) analysis to ascertain the associations between rs738409 and a range of phenotypic traits. This analysis suggests that these QTLs may underpin pleiotropic effects on extrahepatic traits. Finally, we outline potential avenues for further research and identify key areas for investigation in future studies.

Keywords: PNPLA3; HSD17B13; MASH; MASLD; genetics; rs6006460; rs738409.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Worldwide allele frequency distribution of PNPLA3 rs738409 I148M. Allele frequencies are based on data from the 1000 Genomes Project and gnomAD database, downloaded from NCBI dbSNP: https://www.ncbi.nlm.nih.gov/snp/rs738409/. Estimates of SLD prevalence derived from recent meta‐analyses and population‐based studies [1, 22, 23, 24, 25, 26, 27, 28].
FIGURE 2
FIGURE 2
cis‐eQTLs associated with variant: rs738409 (22:43928847_C/G) and various phenotypic traits. This analysis employed a range of resources, including FIVEx [54], and the QTLbase.

Similar articles

Cited by

References

    1. Younossi Z. M., Golabi P., Paik J. M., Henry A., Van Dongen C., and Henry L., “The Global Epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review,” Hepatology 77 (2023): 1335–1347, 10.1097/HEP.0000000000000004. - DOI - PMC - PubMed
    1. Quek J., Chan K. E., Wong Z. Y., et al., “Global Prevalence of Non‐Alcoholic Fatty Liver Disease and Non‐Alcoholic Steatohepatitis in the Overweight and Obese Population: A Systematic Review and Meta‐Analysis,” Lancet Gastroenterology & Hepatology 8 (2023): 20–30, 10.1016/S2468-1253(22)00317-X. - DOI - PubMed
    1. Younossi Z. M., Golabi P., de Avila L., et al., “The Global Epidemiology of NAFLD and NASH in Patients With Type 2 Diabetes: A Systematic Review and Meta‐Analysis,” Journal of Hepatology 71 (2019): 793–801, 10.1016/j.jhep.2019.06.021. - DOI - PubMed
    1. Estes C., Anstee Q. M., Arias‐Loste M. T., et al., “Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the Period 2016–2030,” Journal of Hepatology 69 (2018): 896–904, 10.1016/j.jhep.2018.05.036. - DOI - PubMed
    1. Sookoian S. and Pirola C. J., “Genetic Predisposition in Nonalcoholic Fatty Liver Disease,” Clinical and Molecular Hepatology 23 (2017): 1–12, 10.3350/cmh.2016.0109. - DOI - PMC - PubMed